FTC Pens New Deal With Teva On Reverse-Payment Claims
The Federal Trade Commission said Tuesday it has reached an agreement with Teva Pharmaceuticals that would prevent the drugmaker from entering into certain reverse-payment patent settlements that can delay the availability...To view the full article, register now.
Already a subscriber? Click here to view full article